These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17979686)

  • 1. Immunology of neonatal gene transfer.
    Ponder KP
    Curr Gene Ther; 2007 Oct; 7(5):403-10. PubMed ID: 17979686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
    Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME
    Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
    Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
    Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of regulatory T cells in gene transfer.
    Cao O; Furlan-Freguia C; Arruda VR; Herzog RW
    Curr Gene Ther; 2007 Oct; 7(5):381-90. PubMed ID: 17979684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for hemophilia.
    Ponder KP
    Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance induction by viral in vivo gene transfer.
    Dobrzynski E; Herzog RW
    Clin Med Res; 2005 Nov; 3(4):234-40. PubMed ID: 16303889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance induction by gene transfer to lymphocytes.
    Skupsky J; Su Y; Lei TC; Scott DW
    Curr Gene Ther; 2007 Oct; 7(5):369-80. PubMed ID: 17979683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in gene therapy: averting the immune response to adenoviral vectors.
    Ritter T; Lehmann M; Volk HD
    BioDrugs; 2002; 16(1):3-10. PubMed ID: 11908997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.
    Sarukhan A; Camugli S; Gjata B; von Boehmer H; Danos O; Jooss K
    J Virol; 2001 Jan; 75(1):269-77. PubMed ID: 11119597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance.
    Bhatt KH; Rudraraju R; Brooks JF; Jung JW; Galea R; Wells JW; Steptoe RJ
    Stem Cell Res Ther; 2017 Mar; 8(1):57. PubMed ID: 28279220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sheep model of in utero gene therapy.
    Porada CD; Park P; Almeida-Porada G; Zanjani ED
    Fetal Diagn Ther; 2004; 19(1):23-30. PubMed ID: 14646413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.
    Mingozzi F; Liu YL; Dobrzynski E; Kaufhold A; Liu JH; Wang Y; Arruda VR; High KA; Herzog RW
    J Clin Invest; 2003 May; 111(9):1347-56. PubMed ID: 12727926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
    J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.